We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$511M
AUM Growth
+$1.51M
Cap. Flow
-$202K
Cap. Flow %
-0.04%
Top 10 Hldgs %
52.15%
Holding
56
New
12
Increased
14
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
ZURA icon
Zura Bio
ZURA
+$26.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$15.9M
3
ALKS icon
Alkermes
ALKS
+$12.5M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.2M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.38M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$21.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$17.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$16.9M
4
KALV
KalVista Pharmaceuticals
KALV
+$12.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
26
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.65M 1.3%
+601,322
New +$8.38M
FDMT icon
27
4D Molecular Therapeutics
FDMT
$532M
$6.32M 1.24%
+350,000
New +$6.44M
GBIO
28
DELISTED
Generation Bio
GBIO
$5.62M 1.1%
102,254
– –
HRTX icon
29
Heron Therapeutics
HRTX
$93.9M
$5.5M 1.08%
4,737,368
-1,080,000
-19% -$1.93M
ABOS icon
30
Acumen Pharmaceuticals
ABOS
$155M
$5.06M 0.99%
1,051,267
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$4.62M 0.9%
+500,000
New +$5.6M
MCRB icon
32
Seres Therapeutics
MCRB
$46.8M
$4.49M 0.88%
+46,903
New +$5.1M
DTIL icon
33
Precision BioSciences
DTIL
$180M
$3.93M 0.77%
248,991
-21,002
-8% -$480K
SLDB icon
34
Solid Biosciences
SLDB
$794M
$3.06M 0.6%
584,458
+374,053
+178% +$2.11M
ACRS icon
35
PUT
Aclaris Therapeutics
ACRS
$726M
$2.64M 0.52%
+255,000
New +$2.31M
TRML
36
DELISTED
Tourmaline Bio
TRML
$2.02M 0.4%
+66,603
New +$1.7M
ACLX
37
DELISTED
Arcellx
ACLX
$1.19M 0.23%
37,500
-219,506
-85% -$8.39M
TVTX icon
38
Travere Therapeutics
TVTX
$5.2B
$922K 0.18%
60,000
-943,000
-94% -$17.2M
MRSN
39
CALL
DELISTED
Mersana Therapeutics
MRSN
$230K 0.05%
+2,800
New +$410K
XENE icon
40
PUT
Xenon Pharmaceuticals
XENE
$6.06B
$104K 0.02%
+2,700
New +$107K
ACRS icon
41
CALL
Aclaris Therapeutics
ACRS
$726M
– –
-250,000
Closed -$2.02M
AVTX icon
42
Avalo Therapeutics
AVTX
$965M
– –
-1,978
Closed -$831K
DAWN
43
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-141,526
Closed -$1.89M
ETNB
44
DELISTED
89bio
ETNB
– –
-250,000
Closed -$3.81M
JAZZ icon
45
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-149,500
Closed -$21.9M
KALV
46
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,600,545
Closed -$12.6M
LRMR icon
47
Larimar Therapeutics
LRMR
$397M
– –
-900,000
Closed -$4.08M
MLTX icon
48
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-278,334
Closed -$5.95M
PRAX icon
49
Praxis Precision Medicines
PRAX
$8.58B
– –
-135,503
Closed -$1.64M
RLAY icon
50
Relay Therapeutics
RLAY
$4.1B
– –
-658,127
Closed -$10.8M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Great Point Partners held 56 positions worth $511M, up 0.3% from $509M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners's Q2 2023 filing shows 12 new, 14 increased, 11 reduced and 16 closed positions. Its largest new stake was Zura Bio: 3,295,000 shares worth $27M. The largest sale was Jazz Pharmaceuticals, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • Great Point Partners's largest Q2 2023 buy was Zura Bio: 3,295,000 shares worth $27M.
  • Great Point Partners added most to Rhythm Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • Great Point Partners's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $17.2M.
  • Great Point Partners fully exited Jazz Pharmaceuticals in Q2 2023, selling an estimated $21.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $511M portfolio in Q2 2023.
  • Great Point Partners opened 12 new positions and closed 16 in Q2 2023.
  • Great Point Partners's portfolio value rose 0.3% quarter-over-quarter to $511M.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.